| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 唐寅灏 | 中信证券 | 医药生物 | 50.81% | 56.52% | 33.60% | 60.00% | 13 | -8.47% | 2025-07-07 |
| 2 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.73% | 53.70% | 50.93% | 3.45% | 2 | -27.10% | 2025-04-21 |
| 3 | 胡博新 | 华鑫证券 | 医药生物 | 50.71% | 52.44% | 48.03% | -6.38% | 4 | -51.98% | 2025-08-04 |
| 4 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.69% | 55.04% | 39.12% | 3.45% | 7 | -27.10% | 2025-05-19 |
| 5 | 赵海春 | 国金证券 | 医药生物 | 50.64% | 55.74% | 58.27% | -23.08% | 2 | -61.07% | 2025-07-23 |
| 6 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.60% | 53.65% | 43.16% | 3.45% | 7 | -27.10% | 2025-05-16 |
| 7 | 唐寅灏 | 中信证券 | 医药生物 | 50.55% | 50.55% | 23.31% | 60.00% | 12 | -8.47% | 2025-07-01 |
| 8 | 刘浩 | 华创证券 | 医药生物 | 50.52% | 53.57% | 58.52% | 20.00% | 1 | -47.33% | 2025-04-11 |
| 9 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.15% | 53.94% | 50.92% | 3.45% | 5 | -27.10% | 2025-04-29 |
| 10 | 夏禹 | 国联民生 | 医药生物 | 50.12% | 48.14% | 22.00% | 20.00% | 7 | -52.01% | 2025-08-08 |
| 11 | 夏禹 | 国联民生 | 医药生物 | 50.02% | 49.81% | 19.86% | 20.00% | 7 | -52.01% | 2025-07-25 |
| 12 | 唐寅灏 | 中信证券 | 医药生物 | 49.83% | 57.40% | 30.57% | 60.00% | 13 | -8.47% | 2025-07-08 |
| 13 | 胡博新 | 华鑫证券 | 医药生物 | 49.81% | 54.47% | 47.14% | -6.38% | 4 | -51.98% | 2025-07-31 |
| 14 | 唐寅灏 | 中信证券 | 医药生物 | 49.73% | 57.17% | 31.71% | 60.00% | 13 | -8.47% | 2025-07-09 |
| 15 | 夏禹 | 国联民生 | 医药生物 | 49.72% | 44.50% | 31.21% | 20.00% | 7 | -52.01% | 2025-06-13 |
| 16 | 韩世通 | 中信证券 | 医药生物 | 49.60% | 50.64% | 37.55% | -8.70% | 6 | -63.25% | 2025-07-31 |
| 17 | 夏禹 | 国联民生 | 医药生物 | 49.57% | 42.72% | 36.24% | 20.00% | 7 | -52.01% | 2025-06-03 |
| 18 | 李安飞 | 广发证券 | 医药生物 | 49.35% | 46.26% | 45.58% | 2.86% | 1 | -56.96% | 2025-04-30 |
| 19 | 胡博新 | 华鑫证券 | 医药生物 | 49.33% | 53.25% | 46.67% | -6.38% | 4 | -51.98% | 2025-08-05 |
| 20 | 赵海春 | 国金证券 | 医药生物 | 49.31% | 53.48% | 59.57% | -23.08% | 2 | -61.07% | 2025-07-29 |